For reasons that are not fully understood, MDM2 inhibition has been more successful in other malignancies such as acute myelogenous leukemia, chronic lymphocytic leukemia, and multiple myeloma, in which early-phase clinical trials have demonstrated efficacy (127–129). Here, MDM2 is linked to plasma cell myeloma.